1. Banks TE, Rajapaksha M, Zhang LH, Bai F, Wang NP, Zhao ZQ. Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension. Eur J Pharmacol 2022; 927: 175048.
2. Stacey RB, Hundley WG. Integrating measures of myocardial fibrosis in the transition from hypertensive heart disease to heart failure. Curr Hypertens Rep 2021; 23: 22.
3. Meagher PB, Lee XA, Lee J, Visram A, Friedberg MK, Connelly KA. Cardiac fbrosis: Key role of integrins in cardiac homeostasis and remodeling. Cells 2021; 10: 770-788.
4. Wen ZZ, Cai MY, Mai Z, Jin DM, Chen YX, Huang H, et al. Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. PLoS ONE 2013; 8: e67242-67253.
5. Tan Y, Li X, Prabhu SD, Brittian KR, Chen Q, Yin X, et al. Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J Am Coll Cardiol 2012; 59: 1477-1486.
6. Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol 2008; 52: 655-666.
7. Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 2013; 19: 1110-1120.
8. Sun Y. Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction. J Mol Cell Cardiol 2010; 48: 483-489.
9. Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci 2012; 17: 221-231.
10. Su X, Jiang X, Meng L, Dong X, Shen Y, Xin Y. Anticancer activity of sulforaphane: the epigenetic mechanisms and the Nrf2 signaling pathway. Oxidative Med Cell Longev 2018; 2018: 5438179-5438189.
11. JHwang JW, Yao H, Caito S, Sundar IK, Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 2013; 61: 95-110.
12. Gao R, Ma Z, Hu Y, Chen J, Shetty S, Fu J. Sirt1 restrains lung inflammasome activation in a murine model of sepsis. Am J Physiol Lung Cell Mol Physiol 2015; 308: 847-853.
13. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A regulated cell death nexus linking metabolism redox biology, and disease. Cell 2017; 171: 273-285.
14. Chen H, Deng J, Gao H, Song Y, Zhang Y, Sun J, et al. Involvement of the SIRT1-NLRP3 pathway in the inflammatory response. Cell Commun Signal 2023; 21: 185-196.
15. Yang D, Tan X, Lv Z, Liu B, Baiyun R, Lu J, et al. Regulation of Sirt1/Nrf2/TNF-α signaling pathway by luteolin is critical to attenuate acute mercuric chloride exposure induced hepatotoxicity. Sci Rep 2016; 6: 37157-37169.
16. Xu F, Xu J, Xiong X, Deng Y. Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep 2019; 24: 70-74.
17. Song B, Huang G, Xiong Y, Liu J, Xu L, Wang Z, et al. Inhibitory effects of salidroside on nitric oxide and prostaglandin E2 production in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Med Food 2013; 16: 997-1003.
18. Zhang Y, Yao Y, Wang H, Guo Y, Zhang H, Chen L. Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment. Chin J Cancer Res 2013; 25: 520-526.
19. Zhu Y, Shi YP, Wu D, Ji YJ, Wang X, Chen HL, et al. Salidroside protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via PI3K-Akt dependent pathway. DNA Cell Biol 2011; 30: 809-819.
20. Guan S, Xiong Y, Song B, Song Y, Wang D, Chu X, et al. Protective effects of salidroside from Rhodiola rosea on LPS-induced acute lung injury in mice. Immunopharmacol Immunotoxicol 2012; 34: 667-672.
21. Lu R, Wu Y, Guo H, Huang X. Salidroside protects lipopolysaccharide-induced acute lung injury in mice. Dose-Response 2016; 14: 1-5.
22. Daugherty A, Rateri D, Hong L, Balakrishnan A. Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp 2009; 27: 1291-1293.
23. Duan C, Montgomery MK, Chen X, Ullas S, Stansfield J, McElhanon K, et al. Fully automated mouse echocardiography analysis using deep convolutional neural networks. Am J Physiol Heart Circ Physiol 2022; 4: H628-H639.
24. Ji Y, Ning Z. Paeoniflorin inhibits atrial fibrosis and atrial fibrillation in angiotensin II-infused mice through the PI3K-Akt pathway. Dose-Response 2024; 22: 1-13.
25. Hayrapetyan H, Tran T, Tellez-Corrales E, Madiraju C. Enzyme-linked immunosorbent assay: Types and applications. Methods Mol Biol 2023; 2612: 1-17.
26. Wu Y, Can J, Hao S, Qiang X, Ning Z. LOXL2 inhibitor attenuates angiotensin ii-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of transforming growth factor Beta-1 Smad2/3 pathway. Cerebrovasc Dis 2022; 51: 188-198.
27. Wu Y, Ning Zh. Echinacoside alleviates Ang II-induced cardiac fibrosis by enhancing the SIRT1/IL-11 pathway. Iran J Basic Med Sci 2025; 28: 130-139.
28. Sun J, Wang R, Chao T, Peng J, Wang Ch, Chen K, et al. Ginsenoside Re inhibits myocardial fibrosis by regulating miR489/myd88/NF-κB pathway. J Ginseng Res 2023; 47: 218-227.
29. Im K, Mareninov S, Diaz MFP, Yong WH. An introduction to performing immunofluorescence staining. Methods Mol Biol 2019; 1897: 299-311.
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45-51.
31. Mia MM, Cibi DM, Ghani S, Singh A, Tee N, Sivakumar V, et al. Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodeling and improves cardiac function. Cardiovasc Res 2022; 118: 1785-1804.
32. Ma J, Li Y, Ji X, Wang A, Lan Y, Ma L. Integrating network pharmacology and experimental verification to explore the mechanisms of salidroside against myocardial fibrosis. Biochem Biophys Res Commun 2023; 677: 38-44.
33. Chen P, Liu J, Ruan H, Zhang M, Wu P, Yimei D, et al. Protective effects of Salidroside on cardiac function in mice with myocardial infarction. Sci Rep 2019; 9: 18127-18138.
34. Magani SKJ, Mupparthi SD, Gollapalli BP, Shukla D, Tiwari AK, Gorantala J, et al. Salidroside - can it be a multifunctional Drug? Curr Drug Metab 2020; 21: 512-524.
35. Yang S, Pei T, Wang L, Zeng Y, Li W, Yan S, et al. Salidroside alleviates renal fibrosis in SAMP8 mice by inhibiting ferroptosis. Molecules 2022; 27: 8039-8056.
36. Qu B, Liu X, Liang Y, Zheng K, Zhang C, Lu L. Salidroside in the treatment of NAFLD/NASH. Chem Biodivers 2022; 19: e202200401.
37. Morley ME, Riches K, Peers C, Porter KE. Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodeling. Biochem Soc Trans 2007; 35: 905-907.
38. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res 2021; 117: 1450-1488.
39. Hai Z, Wu Y, Ning Z. Salidroside attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II through inhibition of LOXL2-TGF-β1-Smad2/3 pathway. Heliyon 2023; 9: e21220-1230.
40. Li X, Mo N, Li Z. Ginsenosides: Potential therapeutic source for fibrosis-associated human diseases. J Ginseng Res 2020; 44: 386-398.
41. Stone RC, Chen V, Burgess J, Pannu S, Tomic-Canic M. Genomics of human fibrotic diseases: Disordered wound healing response. Int J Mol Sci 2020; 21: 8590-8620.
42. Crosas-Molist E, Fabregat I. Role of NADPH oxidases in the redox biology of liver fibrosis. Redox Biol 2015; 6: 106-111.
43. Ramachandra CJA, Cong S, Chan X, Yap EP, Yu F, Hausenloy DJ. Oxidative stress in cardiac hypertrophy: from molecular mechanisms to novel therapeutic targets. Free Radic Biol Med 2021; 166: 297-312.
44. Hao S, Sui X, Wang J, Zhang J, Pei Y, Guo L, et al. Secretory products from epicardial adipose tissue induce adverse myocardial remodeling after myocardial infarction by promoting reactive oxygen species accumulation. Cell Death Dis 2021; 12: 848-859.
45. Han X, Ding C, Sang X, Peng MY, Yang Q, Ning Y, et al. Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy. Pharmacol Ther 2022; 229: 107983.
46. Bugyei-Twum A, Ford C, Civitarese R, Seegobin J, Advani JL, Desjardins JF, et al. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovasc Res 2018; 114: 1629-1641.
47. Zhao D, Sun X, Lv S, Sun M, Guo H, Zhai Y, et al. Salidroside attenuates oxidized low-density lipoprotein-induced endothelial cell injury via promotion of the AMPK/SIRT1 pathway. Int J Mol Med 2019; 43: 2279-2290.
)